Download PDF
Thromb Haemost 1984; 52(02): 154-156
DOI: 10.1055/s-0038-1661161
Original Article
Schattauer GmbH Stuttgart

Masking of Fibrinolytic Response to Stimulation by an Inhibitor of Tissue-Type Plasminogen Activator in Plasma

E J P Brommer
The Gaubius Institute, Health Research Division TNO, Leiden, The Netherlands
,
J H Verheijen
The Gaubius Institute, Health Research Division TNO, Leiden, The Netherlands
,
G T G Chang
The Gaubius Institute, Health Research Division TNO, Leiden, The Netherlands
,
D C Rijken
The Gaubius Institute, Health Research Division TNO, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 04 December 1983

Accepted 03 July 1984

Publication Date:
19 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Patients with hyperlipoproteinaemia or spontaneous thromboembolism, known to be poor responders to DDAVP or to venous occlusion with regard to the rise in fibrinolytic activity of the blood, appeared to show a normal increase in t-PA-antigen after the same procedure. In their plasma a higher than normal level of free, fast-acting t-PA-inhibitor was found as measured by titration with purified t-PA. This free t-PA-inhibitor level only decreased after the test, in contrast to its complete disappearance in normal responders. The same happened in a healthy volunteer who failed to exhibit a rise in fibrinolytic activity after exhaustive exercise.

We suppose that the lack of response of the fibrinolytic activity in these cases is due to a high inhibitor level and not to impaired release of t-PA into the blood.

In contrast, patients with terminal renal insufficiency showed only a slight increase in t-PA-antigen after DDAVP. The level of free fast-acting inhibitor was normal in most cases and did not change appreciably during DDAVP-infusion. In these patients, a true impairment of the release of t-PA appears to exist.

Keywords

t-PA-inhibitor - Standard - DDAVP - Exercise - Venous occlusion
 

  • References

  • 1 Nilsson IM, Pandolfi M, Robertson B. Properties of fibrinolytic activators appearing after venous stasis and intravenous injection of nicotinic acid. Coagulation 1970; 3: 13-21
    PubMedGoogle Scholar
  • 2 Kluft C. Studies on the fibrinolytic system in human plasma: Quantitative determination of plasminogen activators and proactivators. Thromb Haemostas 1979; 41: 365-383
    PubMedGoogle Scholar
  • 3 Rijken DC, Wijngaards G, Welbergen J. Relationship between uterine tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980; 18: 815-830
    CrossrefPubMedGoogle Scholar
  • 4 Brommer EJ P, Barrett-Bergshoeff MM, Allen RA, Schicht I, Bertina RM, Schalekamp MA D H. The use of desmopressin acetate (DD AVP) as a test of the fibrinolytic capacity of patients - Analysis of responders and non-responders. Thromb Haemostas 1982; 48: 156-161
    PubMedGoogle Scholar
  • 5 Wiman B, Mellbring G, Rånby M. Plasminogen activator release during venous stasis and exercise as determined by a new specific assay. Clin Chim Acta 1983; 127: 279-288
    CrossrefPubMedGoogle Scholar
  • 6 Rijken DC, Julian-Vague I, De CockF, Collen D. Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay. J Lab Clin Med 1983; 101: 274-284
    PubMedGoogle Scholar
  • 7 Cash J. A new approach to studies of the fibrinolytic enzyme system in man. Am Heart J 1968; 75: 424-427
    CrossrefPubMedGoogle Scholar
  • 8 Isacson S, Nilsson IM. Defective fibrinolysis in blood and vein walls in recurrent “idiopathic” venous thrombosis. Acta Chir Scand 1972; 138: 313-319
    PubMedGoogle Scholar
  • 9 Browse NL, Gray L, Jarrett PE M, Morland M. Blood and vein-wall fibrinolytic activity in health and vascular disease. Br Med J 1977; 1: 478-481
    CrossrefPubMedGoogle Scholar
  • 10 Johansson L, Hedner U, Nilsson IM. A family with thromboembolic disease associated with deficient fibrinolytic activity in vessel wall. Acta Med Scand 1978; 203: 477-480
    PubMedGoogle Scholar
  • 11 Dreyer NA, Pizzo SV. Blood coagulation and idiopathic thromboembolism among fertile women. Contraception 1980; 22: 123-135
    CrossrefPubMedGoogle Scholar
  • 12 Sundqvist S-B, Hedner U, Kullenberg HK E, Bergentz S-E. Deep venous thrombosis of the arm: a study of coagulation and fibrinolysis. Br Med J 1981; 283: 265-267
    CrossrefPubMedGoogle Scholar
  • 13 Jørgensen M, Mortensen JZ, Madsen AG, Thorsen S, Jacobsen B. A family with reduced plasminogen activator activity in blood associated with recurrent venous thrombosis. Scand J Haematol 1982; 29: 217-223
    PubMedGoogle Scholar
  • 14 Stead NW, Bauer KA, Kinney TR, Lewis JG, Campbell EE, Shifman MA, Rosenberg RD, Pizzo SV. Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIH/von Willebrand’s factor. Am J Med 1983; 74: 33-39
    PubMedGoogle Scholar
  • 15 Hamulyak K, Brommer EJ P, Devilee PP, Hemker HC. Activation of coagulation and fibrinolysis during maximal physical exercise. Int J Sport Med. (in press)
    PubMedGoogle Scholar
  • 16 Loskutoff DJ, Edgington TS. Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci 1977; 74: 3903-3907
    CrossrefPubMedGoogle Scholar
  • 17 Levin E, Loskutoff DJ. Comparative studies of the fibrinolytic activity of cultured vascular cells. Thromb Res 1979; 15: 869-878
    CrossrefPubMedGoogle Scholar
  • 18 Loskutoff DJ, Edgington TS. An inhibitor of plasminogen activator in rabbit endothelial cells. J Biol Chem 1981; 256: 4142-4145
    PubMedGoogle Scholar
  • 19 Emeis JJ, van Hinsbergh VW M, Verheijen JH, Wijngaards G. Inhibition of tissue-type plasminogen activator by conditioned medium from cultured human and porcine vascular endothelial cells. Biochem Biophys Res Commun 1983; 110: 392-398
    CrossrefPubMedGoogle Scholar
  • 20 Verheijen JH, Chang GT G, Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemostas. (in press)
    PubMedGoogle Scholar
  • 21 Verheijen JH, Rijken DC, Brommer EJ P, Chang GT G. Measurement of tissue-type plasminogen activator activity, antigen and inhibition in plasma. In: Clinical Aspects of Fibrinolysis and Thrombolysis. Jespersen J, Kluft C. (Eds) South Jutland University Press; Esbjerg, Denmark: 1983. pp 121-131
    Google Scholar
  • 22 Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436
    CrossrefPubMedGoogle Scholar
  • 23 Kruithof EK O, Ransijn A, Bachmann F. Inhibition of tissue plasminogen activator by human plasma. In: Progress in Fibrinolysis. Davidson JF, Bachmann F, Bouvier CA, Kruithof EK O. (Eds) Churchill Livingstone; Edinburgh: 1983. 6 365-369
    Google Scholar
  • 24 Rijken DC, van Hinsbergh VW M, Sens EH C. Quantitation of tissue-type plasminogen activator in human endothelial cell cultures by use of an enzyme immunoassay. Thromb Res 1984; 33: 145-153
    CrossrefPubMedGoogle Scholar
  • 25 Verheijen JH, Mullaart E, Chang GT, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
    PubMedGoogle Scholar
  • 26 Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-7041
    PubMedGoogle Scholar
  • 27 Verheijen JH, Chang GT G, Mullaart E. Inhibition of extrinsic (tissue-type) plasminogen activator by human plasma: evidence for the occurrence of a fast-acting inhibitor. Thromb Haemostas 1983; 50: 294 (Abstr)
    PubMedGoogle Scholar
  • 28 Brommer EJ P, Gevers LeuvenJ A, Barrett-Bergshoeff MM, Schouten JA. Response of fibrinolytic activity and coagulation factor VIII to stimulation with DDAVP in hyperlipoproteinaemia. J Lab Clin Med 100: 105-114
    PubMedGoogle Scholar